Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440094 | 0.81 | ALDH1A1 (0.57) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL12986333 | 0.80 | MAPT (0.36) | ALDH1A1SOAT1 | |
| SCHEMBL12986377 | 0.80 | MAPT (0.36) | ALDH1A1SOAT1 | |
| SCHEMBL12986335 | 0.80 | MAPT (0.36) | ALDH1A1SOAT1 | |
| SCHEMBL180145 | 0.80 | CTSK (0.38) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL304879 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL12185999 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL5965095 | 0.77 | ALDH1A1 (0.35) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL19018678 | 0.77 | HCAR2 (0.38) | ALDH1A1CTSKSOAT1 | |
| SCHEMBL16904019 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3992194-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | West China Hospital, Sichuan University (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-112142746-B | Benzodiazepine compound, preparation method and medical application thereof | 四川大学华西医院 | 2021-09-24 | — | — | CN | disclosed |
| WO-2020259602-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 四川大学华西医院 | 2020-12-30 | — | — | WO | disclosed |
| CN-112142746-A | Benzodiazepine compound, preparation method and medical application thereof | 四川大学华西医院 | 2020-12-29 | — | — | CN | disclosed |
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| CN-102947291-B | Prodrugs of triazolone compounds | EISAI R&D MAN CO LTD | 2014-07-09 | — | — | CN | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-6069249-A | CHEMICAL INTERMEDIATES; DETECTION LABELS FOR NUCLEOTIDE PROBES | GILEAD SCIENCES, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5753672-A | ANGIOTENSIN ANTAGONIST, HYPOTENSIVE | TANABE SEIYAKU CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0682023-B1 | Imidazopyridine derivatives and process for preparing the same | TANABE SEIYAKU CO (JP) | 1997-02-12 | — | — | EP | disclosed |
| CN-1112925-A | Imidazopyridine derivatives and process for preparing the same | TANABE SEIYAKU CO (JP) | 1995-12-06 | — | — | CN | disclosed |
| EP-0682023-A1 | Imidazopyridine derivatives and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | ALDH1A1 305/4885CTSK 774/4885SOAT1 1923/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ALDH1A1 305/4885CTSK 774/4885SOAT1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.